Adaptive Biotechnologies (ADPT) Net Income towards Common Stockholders (2018 - 2026)
Adaptive Biotechnologies (ADPT) posted Net Income towards Common Stockholders of -$53.0 million for Q1 2026, down 267.09% sequentially from -$14.4 million in Q4 2025, and down 77.12% YoY from -$231.7 million in Q1 2025.
Adaptive Biotechnologies (ADPT) Net Income towards Common Stockholders (2018 - 2026) Analysis & Trends
Adaptive Biotechnologies has reported Net Income towards Common Stockholders for 9 years, with the latest figure at -$53.0 million in Q1 2026.
- Quarterly Net Income towards Common Stockholders fell 77.12% year-over-year to -$53.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$181.2 million (down 30.07% YoY) and the FY2025 annual result came in at -$62.0 million, up 61.67% from the prior year.
- Net Income towards Common Stockholders retreated to -$53.0 million in Q1 2026 per ADPT's latest filing, from -$14.4 million in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at $9.5 million in Q3 2025 and troughed at -$208.7 million in Q1 2022.
- A 5-year average of -$56.3 million and a median of -$48.2 million in 2024 frame the typical range for Net Income towards Common Stockholders.
- The widest YoY moves for Net Income towards Common Stockholders: up 129.74% in 2025, down 166.51% in 2025.
- Over 5 years, Net Income towards Common Stockholders stood at -$38.9 million in 2022, then tumbled by 78.65% to -$69.5 million in 2023, then jumped by 55.37% to -$31.0 million in 2024, then surged by 53.42% to -$14.4 million in 2025, then plunged by 267.09% to -$53.0 million in 2026.
- According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$53.0 million, -$14.4 million, and $9.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Thermo Fisher Scientific | 213.88 Bn | 209.81 Bn | 8.34 Bn | 1.76 Bn |
| 2 | Danaher | 140.65 Bn | 136.30 Bn | 3.61 Bn | 870.00 Mn |
| 3 | Idexx Laboratories | 46.02 Bn | 45.83 Bn | 779.09 Mn | 338.41 Mn |
| 4 | Agilent Technologies | 39.85 Bn | 38.05 Bn | 990.00 Mn | 339.00 Mn |
| 5 | Iqvia Holdings | 39.20 Bn | 37.12 Bn | 1.44 Bn | 241.00 Mn |
| 6 | Natera | 38.80 Bn | 37.70 Bn | 696.04 Mn | -85.11 Mn |
| 7 | Illumina | 30.11 Bn | 28.94 Bn | 770.00 Mn | 207.00 Mn |
| 8 | Mettler Toledo International | 28.66 Bn | 28.61 Bn | 650.22 Mn | 232.90 Mn |
| 9 | Quest Diagnostics | 26.24 Bn | 25.61 Bn | 1.03 Bn | 324.00 Mn |
| 10 | Adaptive Biotechnologies | 3.80 Bn | 3.58 Bn | 52.17 Mn | -53.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -53.00 Mn |
| Dec 31, 2025 | -14.44 Mn |
| Sep 30, 2025 | 9.55 Mn |
| Jun 30, 2025 | -123.26 Mn |
| Mar 31, 2025 | -29.93 Mn |
| Dec 31, 2024 | -31.00 Mn |
| Sep 30, 2024 | -32.10 Mn |
| Jun 30, 2024 | -46.25 Mn |
| Mar 31, 2024 | -48.24 Mn |
| Dec 31, 2023 | -69.47 Mn |
| Sep 30, 2023 | -50.33 Mn |
| Jun 30, 2023 | -47.81 Mn |
| Mar 31, 2023 | -57.70 Mn |
| Dec 31, 2022 | -38.88 Mn |
| Sep 30, 2022 | -48.85 Mn |
| Jun 30, 2022 | -66.18 Mn |
| Mar 31, 2022 | -208.69 Mn |
| Dec 31, 2021 | -64.06 Mn |
| Sep 30, 2021 | -274.17 Mn |
| Jun 30, 2021 | -350.09 Mn |